← IDEXX LABORATORIES INC /DE (IDXX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
IDEXX LABORATORIES INC /DE (IDXX)
In Vitro & In Vivo Diagnostic Substances · market cap $41.0B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
0
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
IDEXX Laboratories is a mature, large-cap diagnostics company focused on companion animal health, with a $45B market cap and ~$4.3B in 2025 revenues. The company is profitable with $1.06B in 2025 net income and has compounded revenue and earnings steadily over the past five years. The next identifiable catalyst is Q2 2026 earnings on August 4, 2026.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
Pipeline
No pipeline data.
Price & technical context
3-month
-2.9%
6-month
-7.1%
12-month
-17.2%
52-wk range
$504.70–$766.68
vs 50-day MA
-4.1%
vs 200-day MA
-11.5%
Realized vol
31.6%
Max drawdown
-34.2%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IDXX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.